Alnylam Pharmaceuticals
ALNY
#622
Rank
A$50.63 B
Marketcap
$392.56
Share price
2.75%
Change (1 day)
47.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.57. In 2022 the company made an earnings per share (EPS) of -$14.86 a decrease over its 2021 EPS that were of -$11.52.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-59.24%
2022-$14.8629.03%
2021-$11.52-3.36%
2020-$11.92-8.48%
2019-$13.027.67%
2018-$12.0939.74%
2017-$8.6512.94%
2016-$7.6638.84%
2015-$5.52-32.88%
2014-$8.22259.44%
2013-$2.29-31.25%
2012-$3.3352.94%
2011-$2.1830.77%
2010-$1.66-8.77%
2009-$1.8278.13%
2008-$1.02-70.78%
2007-$3.5099.09%
2006-$1.76-43.88%
2005-$3.13-82.33%
2004-$17.74-59.23%
2003-$43.52

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.72-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$59.75-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.52 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.43-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.70-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.98-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.09-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.20-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel